



## Cancer-Induced Immunosuppressive Mechanism

Guest Editor:

**Dr. Malgorzata Czystowska-Kuzmicz**

Chair and Department of  
Biochemistry, Medical University  
of Warsaw, 00-927 Warszawa,  
Poland

Deadline for manuscript  
submissions:

**closed (25 March 2022)**

### Message from the Guest Editor

Dear colleagues,

Low response rates and the frequent lack of long-term benefits in patients have called scientists' and clinicians' attention to the complex crosstalk between tumor and immune cells. Indeed, it has become increasingly clear that tumors use several mechanisms to suppress anti-tumor immunity, within the tumor microenvironment as well as systemically, and that this escape of tumors from the host immune system may be a major barrier to successful immunotherapy. Therefore, the identification and understanding of the various tumor-induced immunosuppressive mechanisms is essential for the future development of effective immunotherapies and may provide new therapeutic targets. This Special Issue will bring together the newest original research, short communications, and review articles on tumor-induced immune suppression, including such topics as immunosuppressive factors, recruitment of suppressive or regulatory cells, immune cell reprogramming, tumor microenvironment editing, immune checkpoints, the role of EVs in cancer/immune cell cross-talk, metabolics, and tumor-derived EVs.

Dr. Malgorzata Czystowska-Kuzmicz  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer  
Institute, Winston-Salem, NC  
27103, USA  
2. Division of Hematologic  
Malignancies and Cellular  
Therapy, Duke University,  
Durham, NC 27710, USA

## Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM; ISSN 2075-4426)* is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

**Journal Rank:** JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Journal of Personalized Medicine*  
Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/jpm](http://mdpi.com/journal/jpm)  
[jpm@mdpi.com](mailto:jpm@mdpi.com)  
[X@JPM\\_MDPI](https://twitter.com/JPM_MDPI)